Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | RFA CA 22 002

Opportunity Information: Apply for RFA CA 22 002

The National Cancer Institute (NCI) is offering this grant opportunity to support projects that push promising new molecular and cellular analysis technologies closer to real-world use in cancer research. The announcement, titled "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)" (Funding Opportunity Number RFA-CA-22-002), is part of NCI's broader Innovative Molecular Analysis Technologies (IMAT) Program. The main idea is to fund technology-focused research that can give scientists new or significantly improved ways to target, probe, measure, or interpret the molecular and cellular characteristics that drive cancer, in ways that can ultimately accelerate discovery and improve outcomes.

This FOA is specifically for the NIH R33 mechanism, which is typically used when an approach has already cleared major feasibility hurdles but still needs meaningful refinement and proof that it works reliably. In practical terms, applicants are expected to have supportive preliminary data showing that the technology basically works and that the key "can this be done at all" questions have been answered. What still remains, and what the grant is meant to fund, is deeper development work plus rigorous validation so that other labs and research teams can confidently adopt the method. The emphasis is not on generating biological findings for their own sake, but on making the technology stronger, more reproducible, better characterized, and ready for broader use by the cancer research community.

Projects should propose emerging technologies that provide genuinely novel capabilities for analyzing cancer at the molecular and/or cellular level. The technologies can be geared toward basic research or clinical research settings, and they should have clear potential to accelerate or improve work in areas such as cancer biology, early detection and screening, clinical diagnosis, treatment and therapeutic decision-making, cancer control, epidemiology, and research that addresses cancer health disparities. The common thread is that the tool or method should improve the quality, depth, speed, or practicality of molecular or cellular characterization of cancer, rather than simply applying a standard approach to a new disease question.

A key boundary in this announcement is what it will not fund. Applications that mainly use existing, established technologies and claim novelty primarily because they are being used on a new tumor type, new biomarker, or new clinical question are considered out of scope and will not be reviewed. In other words, the innovation needs to be in the technology or analytical methodology itself, not just in the biological target. Also, as the title indicates, clinical trials are not allowed under this FOA, meaning the work should not be structured as a clinical trial even if the technology has clinical relevance.

From an administrative standpoint, this is a discretionary NIH grant in the health and education activity category (CFDA/Assistance Listing 93.394). The opportunity listed an award ceiling of $300,000. The original closing date shown in the source information is September 22, 2022, and the FOA was created on November 23, 2021. While those dates indicate this particular cycle has already passed, the summary still reflects how NCI structures and prioritizes this kind of technology-development funding through IMAT.

Eligibility is broad and includes a wide range of organization types. Eligible applicants include state, county, and local governments; special districts; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status; for-profit organizations (other than small businesses) as well as small businesses; and other organizations. The FOA also explicitly highlights additional eligible categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and non-U.S. entities (foreign organizations). This breadth aligns with the program's interest in enabling wide participation and supporting technologies that can ultimately be adopted across diverse research environments, including those that serve populations affected by cancer disparities.

Overall, this opportunity is meant for teams that are beyond the earliest proof-of-concept stage and are ready to make their emerging cancer-relevant molecular or cellular analysis technology more robust, validated, and usable by others. Competitive projects are likely to be those that can clearly explain what is technologically new, what feasibility has already been demonstrated, what specific development and validation steps remain, and how the final product would materially improve cancer research or clinically oriented cancer investigations without crossing into clinical trial territory.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394.
• This funding opportunity was created on 2021-11-23.
• Applicants must submit their applications by 2022-09-22. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $300,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA CA 22 002

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: